Eli Lilly’s metabolic disorder medication tirzepatide, which is approved for type 2 diabetes and weight management, has shown positive early clinical data for treating fatty liver disease (NASH) with no FDA-approved drug therapies. In a Phase 2 trial, 74% of participants on the highest dose of tirzepatide achieved absence of NASH with no worsening of the liver fibrosis, compared to 12.6% on a placebo. Tirzepatide mimics gut hormones to regulate blood sugar and appetite and is also being studied for NASH. This could potentially lead to future FDA approval and competition with other drug candidates for NASH treatment. Despite effective results, ongoing research is required for future developments in the treatment of NASH.
Source link
Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive
